Welcome to our dedicated page for Harrow Health SEC filings (Ticker: HROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harrow, Inc. (HROW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. Harrow is an ophthalmic-focused pharmaceutical company whose common stock trades on the Nasdaq Stock Market, and its filings offer detailed information about its financial condition, capital structure, and material corporate events.
Harrow’s current reports on Form 8-K include disclosures about quarterly financial results, investor presentations, credit agreements, leadership changes at subsidiaries, and business development transactions. For example, recent 8-K filings describe the announcement of financial results for the period ended September 30, 2025, the entry into and terms of a senior secured revolving credit facility with a commercial bank, and the agreement to acquire, and subsequent completion of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies.
The company’s filings also document capital markets and debt activities. Harrow has reported the pricing of senior unsecured notes due 2030 in a private offering and related plans to use the proceeds to repay existing debt and redeem previously issued senior notes. Separate Form 25 filings by the Nasdaq Stock Market LLC show the removal from listing and registration of Harrow’s 8.625% senior notes due 2026 and 11.875% senior notes due 2027.
Through Stock Titan, users can follow Harrow’s 10-K annual reports, 10-Q quarterly reports, and 8-K current reports as they are made available on EDGAR. AI-powered summaries help explain the key points in these documents, including revenue trends, operating results, debt arrangements, and the terms of material agreements such as merger agreements and credit facilities. The filings page also surfaces information relevant to equity and debt investors, including unregistered sales of equity securities disclosed in connection with milestone-based consideration for acquisitions.
For investors analyzing Harrow’s ophthalmic and procedural sedation strategy, the SEC filings provide primary-source detail on transaction structures, milestone obligations, and financial covenants. Stock Titan’s tools are designed to make these complex filings easier to review by highlighting important sections and presenting concise explanations of the underlying disclosures.
Harrow, Inc.’s chief commercial officer, Patrick William Sullivan, received two new restricted stock unit awards. On 01/30/2026 he was granted 25,000 RSUs and 15,000 RSUs under the company’s 2025 Incentive and Awards Plan, each RSU representing one share of Harrow common stock upon vesting.
The 25,000 RSUs have a five-year term and vest only if Harrow’s revenue reaches $230,000,000 in a single calendar quarterly period, tying this award directly to a significant revenue milestone. The 15,000 RSUs will vest in full three years after the grant date, on 01/30/2029, providing longer-term equity-based compensation. Both awards are held directly by Sullivan.
Harrow, Inc. filed a Form 3 for Chief Commercial Officer Patrick William Sullivan, reporting a stock option over 30,000 shares of common stock. The option has an exercise price of $39 per share and expires on September 1, 2035.
According to the vesting schedule, 25% of the option shares vest on the one-year anniversary of the grant date. The remaining shares vest in 12 equal quarterly installments over the following three years, becoming fully vested and exercisable on September 1, 2029. The option is held directly.
Harrow, Inc. filed an update covering its outlook and leadership team. The company reaffirmed its full-year 2025 revenue guidance in a range of $270 million to $280 million, signaling no change to its previously communicated expectations.
Harrow also appointed Patrick W. Sullivan as Chief Commercial Officer, effective January 30, 2026. He brings more than 25 years of commercial leadership experience from roles at Corium Therapeutics, AstraZeneca, Shire, Adolor, Novartis, and Bayer. Under his offer letter, Sullivan will receive a $425,000 annual base salary, a target annual bonus equal to 40% of base compensation, and 40,000 restricted stock units. Of these, 25,000 RSUs vest if Harrow’s revenue reaches $230,000,000 in a calendar quarterly period, and 15,000 RSUs vest three years from the award date.
Harrow, Inc. insider Opaleye Management Inc., a 10% owner, reported an indirect sale of Harrow common stock. On January 6, 2026, a separately managed account for which Opaleye acts as portfolio manager sold 20,000 shares of common stock at a weighted average price of $53.3457 per share. After this transaction, the managed account held 70,000 shares indirectly attributed to Opaleye. Separately, 3,815,000 shares were reported as owned by Opaleye, L.P., for which Opaleye Management Inc. is the investment manager. Opaleye Management Inc. states it may be deemed a beneficial owner through these roles but disclaims beneficial ownership beyond its pecuniary interest.
Harrow, Inc. reported that its president and CFO, Andrew R. Boll, exercised 60,000 stock options on 12/12/2025 at an exercise price of $3.95 per share, receiving the same number of common shares.
The options were originally granted on April 1, 2016 under the company’s 2007 Stock Incentive and Awards Plan and vested quarterly over three years. In connection with the exercise, 26,665 shares were withheld to cover the exercise price and tax liability, and the filing states this withholding did not involve any market sales or other market transactions. After these transactions, Boll beneficially owns 811,179 shares of Harrow common stock directly.
Harrow, Inc.'s chief executive officer and director Mark L. Baum reported exercising stock options for 180,000 shares of common stock at $3.95 per share.
After this option exercise and the withholding of 79,994 shares to satisfy the exercise price and tax obligations, he directly owns 2,986,130 shares of Harrow common stock. The company notes that the share withholding did not involve any market sales or other market transactions.
Harrow, Inc. reported that it has completed the acquisition of Melt Pharmaceuticals, Inc. on November 17, 2025 under a previously announced merger agreement. At closing, Harrow paid approximately $4.3 million in cash as initial consideration for the remaining equity interests of Melt, and the contingent regulatory and commercial milestone payments previously outlined remain in place. The company notes that any potential future issuance of its common stock related to this acquisition would rely on an exemption from registration under Section 4(a)(2) of the Securities Act. Harrow also issued a press release on November 18, 2025 announcing the closing of the Melt acquisition.
Harrow, Inc. (HROW) reported Q3 2025 results, showing strong top-line growth and a swing to profitability for the quarter while executing a major refinancing. Revenue rose to $71.6 million from $49.3 million a year ago, driven mainly by product sales of $71.5 million. Gross profit reached $53.9 million. Operating income was $14.7 million, and net income was $1.0 million (diluted EPS $0.03) versus a prior-year loss.
Year to date, Harrow recorded a net loss of $11.8 million, reflecting higher interest expense and a $7.8 million loss on extinguishment of debt tied to balance sheet changes. The company issued $250.0 million of 8.625% senior notes due 2030 and repaid its Oaktree Loan and 2026/2027 notes in September. Cash and cash equivalents were $74.3 million at quarter end, supported by $35.5 million net cash provided by operating activities for the first nine months of 2025. Shares outstanding were 37,037,453 as of November 10, 2025.
Harrow, Inc. (HROW) furnished materials announcing financial results for the period ended September 30, 2025 and recent corporate updates. The company provided a press release, a stockholder letter, and an investor presentation for reference.
These materials were furnished under Items 2.02 and 7.01 and are not deemed “filed” for liability purposes or incorporated by reference unless expressly stated. Exhibits include a press release, stockholder letter, and a corporate presentation.
Harrow, Inc. director/officer Francis William Mullery Jr. reported an initial beneficial ownership filing dated 10/06/2025. The filing discloses a stock option for 33,000 shares of common stock with an exercise price of $48.18. The option vests 25% after one year and the remainder in equal quarterly installments over the next three years, becoming fully vested and exercisable on 09/30/2029. The form was signed on 10/10/2025.